Trial reportFrontiers in pharmacology2026
Ultrasound-guided transversus abdominis plane block using ropivacaine and different doses of perineural dexmedetomidine for analgesia after cesarean section: a randomized controlled clinical trial.
Trial report in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dexmedetomidine is frequently combined with ropivacaine in ultrasound-guided transversus abdominis plane (TAP) block for analgesia after cesarean section (CS), but is associated with adverse effects. The ideal dose of dexmedetomidine as local anesthetic adjuvant has not been determined. This study aimed to explore the dose of perineural dexmedetomidine for ensuring analgesic efficacy while minimizing adverse effects. Methods: Patients undergoing CS under combined spinal-epidural anesthesia were randomly allocated to five groups: DR (0.00 μg/kg dexmedetomidine), DR1 (0.25 μg/kg), DR2 (0.50 μg/kg), DR3 (0.75 μg/kg), and DR4 (1.00 μg/kg), all combined with ropivacaine for TAP block. The co-primary outcomes were time to first rescue analgesia and total consumption of sufentanil at 48 h. The secondary outcomes included visual analogue scale (VAS) scores; Ramsay Sedation Scale scores; patient satisfaction scores; time to first ambulation; length of hospital stay; and postoperative complications. Success was defined as achieving statistical significance for both primary endpoints. Results: Among 150 enrolled patients, 12 were excluded for protocol violations, leaving 138 participants in the final analysis. With increasing doses of dexmedetomidine, time to first rescue analgesia was significantly prolonged (from 5.42 ± 2.29 h to 11.26 ± 2.48 h; Conclusion: Dexmedetomidine as an adjuvant to ropivacaine in ultrasound-guided TAP block for analgesia after CS, demonstrated a dose-dependent effect. 0.75 μg/kg dexmedetomidine appeared to provide the most favorable balance between analgesic efficacy and safety. Clinical Trial Registration: https://www.chictr.org.cn, identifier ChiCTR2300068207.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.